Novartis Terminates Agreement with Mesoblast (MSB)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. ANT
4. LLY
5. TSLA
6. META
7. FICO
8. SPCX
9. MSFT
10. AZN

Go back to Novartis Terminates Agreement with Mesoblast (MSB)

Update on Novartis Agreement

December 13, 2021 7:18 PM EST

NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX: MSB), global leader in allogeneic cellular medicines for inflammatory diseases, was notified today by Novartis that it has chosen to terminate the agreement with Mesoblast prior to closing. Mesoblast remains highly focused on executing on our short term objective to bring remestemcel-L to market for patients with acute respiratory distress syndrome (ARDS) due to COVID-19.

The observed mortality reduction with remestemcel-L in patients aged under 65 in the completed COVID ARDS trial, despite having missed the primary endpoint, is... More